Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy

Am J Cardiol. 2004 Aug 1;94(3):337-9. doi: 10.1016/j.amjcard.2004.04.028.

Abstract

During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biphenyl Compounds / administration & dosage
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / mortality
  • Diabetic Angiopathies / diagnosis*
  • Diabetic Angiopathies / mortality
  • Diabetic Nephropathies / diagnosis*
  • Diabetic Nephropathies / mortality
  • Electrocardiography*
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension / complications
  • Hypertension / diagnosis*
  • Hypertension / mortality
  • Incidence
  • Irbesartan
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis*
  • Myocardial Infarction / etiology*
  • Myocardial Infarction / mortality
  • Prospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Tetrazoles / administration & dosage
  • Treatment Outcome

Substances

  • Biphenyl Compounds
  • Tetrazoles
  • Irbesartan